Global Ovarian Cancer Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Stage of Cancer, Cancer Type, Diagnosis, Type of Treatment & Region – Industry Forecast (2024 to 2029)

Published: January, 2024
ID: 1391
Pages: 181

Ovarian Cancer Market Size (2023 to 2028)

The size of the global ovarian cancer market is predicted to register a CAGR of 10.1% from 2023 to 2028.

The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spreads to the stomach and pelvis, a very advanced stage of ovarian cancer, which is fatal. A substantial percentage of women are dying due to ovarian cancer across the world. Ovarian cancer shows pious symptoms in the affected women, but they might experience pain in the abdomen, fatigue, indigestion, bloating, and nausea.


The growing women aging population and rising prevalence of ovarian cancer worldwide are majorly accelerating the growth rate of the global ovarian cancer market.

The increasing economies of the countries in the developed and developing regions are leading to the expansion of healthcare. As a result, they are contributing to the growth of the global ovarian cancer market. The global ovarian cancer market is further predicted to develop in response to the growing geriatric population of women, the rise in ovarian cancer incidence, the ease of use of new treatments and therapies, and the increase in healthcare expenditure. In addition, increased government financing is also fuelling the market's expansion.

Ovarian cancer has become more common in recent years as the female population has aged. Some of the other important reasons driving the growth of the ovarian cancer market are rising ovarian cancer prevalence, the launch of new medications and therapies, increased healthcare expenditure, and increased government funding. Furthermore, growing healthcare awareness is propelling the ovarian cancer market forward. As a result, drugs like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to enhance the market, now dominated by generics like paclitaxel and carboplatin. In addition, the market is expected to benefit significantly from the development of new medications to treat this form of cancer.

The global ovarian cancer treatment market is boosted by ongoing research and development to offer effective treatment interventions for various disorders. Several ovarian cancer treatments are now in clinical trials and are likely to hit the market in the near future. In addition, the patent expiration of certain top pharmaceuticals may also help propel the industry by encouraging new companies to enter the market. These altering dynamics are predicted to drive the ovarian cancer market during the forecast period. Additionally, the increasing adoption rate of combination therapies for treatment is another significant factor that catalyzes the growth of this market. Increased funding from governments and private organizations to research and develop effective treatment techniques and advanced therapeutics for treating ovarian cancer is boosting the worldwide ovarian cancer market.


Ovarian cancer symptoms are commonly ignored and readily confused with other illnesses, resulting in a lack of early identification and correct diagnosis. This is impeding the market for ovarian cancer diagnostics and treatments in Asia-Pacific. Ovarian cancer can spread to other organs such as the abdominal cavity, pelvis, and abdominal lymph nodes, bones, liver, brain, and the sac around the lymph nodes, among other things. Furthermore, the global market's expansion is being stifled by the expiration of significant medication patents. In the development of increasingly effective drugs, the market may confront a problem.

In addition, the unavailability of adequate technology for detecting ovarian cancer in the early stages is the major challenge limiting the growth of the global ovarian cancer market. Furthermore, the lack of skilled professionals is challenging the key players in the growth of the market. Also, the lack of funding for research and development activities is challenging the growth of the ovarian cancer market.

Impact of the COVID-19 pandemic on the global ovarian cancer market:

The COVID-19 pandemic has negatively affected many countries across the globe. Several measures introduced to deal with the pandemic, such as lockdowns, reduction in trade activities, and shutdown of multiple factories and workplaces in several countries, could save lives; however, these measures have wide-ranging economic effects inducing economic contagion. Thus, along with the risk of a slowdown of global growth, the results of COVID-19 are adversely affecting various economic sectors in economies across the globe. Key manufacturing segments have halted operations across the globe in response to the lockdown regulations issued by governments of various countries and discontinuing public transport services. In addition, amid the COVID-19 pandemic, the global ovarian cancer therapeutics market is witnessing significant operations changes.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By Stage of Cancer, Diagnosis, Type of Treatment, Type of Cancer, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global ovarian cancer market has been segmented and sub-segmented based on the stage of cancer, diagnosis, type of treatment, type of cancer, and region.

 Ovarian Cancer Market - By Stage of Cancer:

  • Stage I
    • Stage IA
    • Stage IB
    • Stage IC
  • Stage II
    • Stage IIA
    • Stage IIB
    • Stage IIC
  • Stage III
    • Stage IIIA
    • Stage IIIB
    • Stage IIIC
  • Stage IV

Ovarian Cancer Market - By Cancer Type:

  • Primary Peritoneal Carcinoma
  • Ovarian Stromal Tumors
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors

The epithelial ovarian cancer segment is predicted to hold a leading share in the global market during the forecast period based on the cancer type. The rising population and growing awareness of the availability of treatment procedures bolstered the demand for this market. In addition, increasing incidences of ovarian cancer patients propel the growth rate of the ovarian low malignant potential tumor segment.

Ovarian Cancer Market - By Diagnosis:

  • Physical Examination
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • MRI
  • Human Chorionic Gonadotropin Test
  • Biopsy

Ovarian Cancer Market - By Type of Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

Based on the type of treatment, Immunotherapy is dominating the market. It is presumed to grow at a high pace during the forecast period due to the continually increasing adoption rate of immunotherapy treatments and the expansion of healthcare, leading to the rise in the number of patients diagnosed with ovarian cancer undergoing immunotherapy.

The targeted therapy market is continuously increasing at a high rate of CAGR. It is likely to continue the trend during the forecast period due to the increasing popularity of targeted therapies and the rising prevalence of women affected by ovarian cancer.  

Ovarian Cancer Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America accounted for the leading share of the global ovarian cancer market in 2022. It is assumed to continue the trend during the outlook period due to the increasing pervasiveness of ovarian cancer and the geriatric population's growing account. The United States controls the highest share in the ovarian cancer diagnostics and therapeutics market and has added significantly. Ovarian cancer is the ninth most common cancer and the fifth leading cause of cancer death among women in the United States. Furthermore, most of the top global ovarian cancer diagnostics players are based in the United States. Therefore, it tends to be a significant advantage for the region, expected to drive the market.

Asia-Pacific demand is contributing a significant share of revenues to the market. It is likely to witness growth at a high CAGR during the projection period due to the increasing prevalence of the aged population and the growing economies of countries like China and India. India and China are the fastest emerging countries in the Asia Pacific, owing to rising healthcare expenditures, increased government support, and an expanding target patient pool. Every year, more than 7 million new cancer cases are identified in Asia, according to the World Health Organization (WHO). China and India are regarded as two of the most promising countries globally, with substantial market prospects. Rising ovarian cancer incidence, favorable medical care reforms, increased health awareness, a low-cost base, and a lack of legal and cultural barriers contribute to the market's growth in India and China. As a result, the Asia-Pacific ovarian cancer diagnostics market is growing at a rapid pace.

Furthermore, the Asia-Pacific ovarian cancer diagnostics and therapeutics market is being fuelled by increased usage of combination treatments to treat ovarian cancer and rising healthcare spending in particular parts of the region. Ovarian cancer is becoming more common in China, which is leading the market. As a result, the projected incidence of ovarian cancer among Chinese women is rising.


Companies leading the global ovarian cancer market profiled in the report are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.


  • GlaxoSmithKline plc has developed a novel drug for women diagnosed with advanced ovarian cancer. The company approved a drug called zejula to the FDA in February 2020; the FDA aims for an efficient reviewing process to make it available for patients.
  • In the recent studies, the researchers have identified a new drug fragment; as per the reports published by the research team, the pieces can help analyze the function of cancer protein leading to the development of drugs in the future.

Please wait. . . . Your request is being processed

Frequently Asked Questions

What are the factors driving the growth of the ovarian cancer market?

The increasing prevalence of ovarian cancer, growing aging population, and advancements in medical technology are the key factors driving the growth of the ovarian cancer market.

What are the challenges faced by the ovarian cancer market?

The high cost of ovarian cancer drugs, limited treatment options for some types of ovarian cancer, and the lack of effective screening tools for early detection are some of the challenges faced by the ovarian cancer market.

Who are the key players in the ovarian cancer market?

Some of the key players in the ovarian cancer market include AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Roche Holding AG.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample